PEDIACEL 20 MCG / 0.5 ML — DIN 02243167
PERTUSSIS TOXOID 20 MCG; FILAMENTOUS HAEMAGGLUTININ 20 MCG; FIMBRIAE 5 MCG; PERTACTIN 3 MCG; DIPHTHERIA TOXOID 15 LF; TETANUS TOXOID 5 LF; INACTIVATED POLIOMYELITIS VACCINE (V.C.O.) TYPE 1 MAHONEY 29 UNIT; INACTIVATED POLIOMYELITIS VACCINE (V.C.O.) TYPE 2 MEF1 7 UNIT; INACTIVATED POLIOMYELITIS VACCINE (V.C.O.) TYPE 3 SAUKETT 26 UNIT; HAEMOPHILUS INFLUENZAE TYPE B-PRP 10 MCG; TETANUS PROTEIN 30 MCG · SANOFI VACCINES CANADA LTD. · SUSPENSION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is PEDIACEL?
PEDIACEL 20 MCG / 0.5 ML contains PERTUSSIS TOXOID 20 MCG; FILAMENTOUS HAEMAGGLUTININ 20 MCG; FIMBRIAE 5 MCG; PERTACTIN 3 MCG; DIPHTHERIA TOXOID 15 LF; TETANUS TOXOID 5 LF; INACTIVATED POLIOMYELITIS VACCINE (V.C.O.) TYPE 1 MAHONEY 29 UNIT; INACTIVATED POLIOMYELITIS VACCINE (V.C.O.) TYPE 2 MEF1 7 UNIT; INACTIVATED POLIOMYELITIS VACCINE (V.C.O.) TYPE 3 SAUKETT 26 UNIT; HAEMOPHILUS INFLUENZAE TYPE B-PRP 10 MCG; TETANUS PROTEIN 30 MCG. It is listed in the Health Canada Drug Product Database under DIN 02243167, held by SANOFI VACCINES CANADA LTD., supplied as SUSPENSION for INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 14-Nov-2024. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is PEDIACEL used for?
Primary immunization of infants (from 2 months) and children up to 6 years against diphtheria, tetanus, pertussis, poliomyelitis and invasive H. influenzae type b disease.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Dipht-Hemoph Influen B-Pertuss-Polio-Tetanus in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
3 holders have a Canadian DIN containing Dipht-Hemoph Influen B-Pertuss-Polio-Tetanus, across 4 DINs, of which 2 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANOFI PASTEUR LIMITED | 2 | 1 | PENTACEL | Sourceable in Canada |
| GLAXOSMITHKLINE INC | 1 | 1 | INFANRIX-IPV/HIB | Sourceable in Canada |
| SANOFI VACCINES CANADA LTD. | 1 | 0 | PEDIACEL | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 20 MCG / 0.5 ML |
|---|---|
| Dosage form | SUSPENSION |
| Route | INTRAMUSCULAR |
| Pack configuration (monograph) | Single dose (0.5 mL) vials, available in packages of 1 or 5 vials. Vials are Type 1 glass; latex-free closure. |
| Storage | Store at 2° to 8°C (35° to 46°F). Do not freeze. (Note: inferred from standard vaccine storage in text context, though section 11 is truncated in snippet). |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Dipht-Hemoph Influen B-Pertuss-Polio-Tetanus |
|---|---|
| ATC code | J07CA06 |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02243167 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2243167 |
| Brand name | PEDIACEL |
| Generic / active ingredient | PERTUSSIS TOXOID 20 MCG; FILAMENTOUS HAEMAGGLUTININ 20 MCG; FIMBRIAE 5 MCG; PERTACTIN 3 MCG; DIPHTHERIA TOXOID 15 LF; TETANUS TOXOID 5 LF; INACTIVATED POLIOMYELITIS VACCINE (V.C.O.) TYPE 1 MAHONEY 29 UNIT; INACTIVATED POLIOMYELITIS VACCINE (V.C.O.) TYPE 2 MEF1 7 UNIT; INACTIVATED POLIOMYELITIS VACCINE (V.C.O.) TYPE 3 SAUKETT 26 UNIT; HAEMOPHILUS INFLUENZAE TYPE B-PRP 10 MCG; TETANUS PROTEIN 30 MCG |
| Market authorization holder | SANOFI VACCINES CANADA LTD. |
| Health Canada schedule | Schedule D |
| ATC code | J07CA06 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J07CA |
| Current status | CANCELLED POST MARKET |
| Status date | 14-Nov-2024 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
0.5 mL dose at 2, 4, 6, and 18 months of age. Administer by intramuscular injection. Shake well before use.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to any component; Encephalopathy within 7 days of a pertussis vaccine; Progressive neurologic disorder (infantile spasms, uncontrolled epilepsy) until stabilized.
Warnings and precautions
Not for treatment of active disease. Postpone in acute/febrile disease. Caution if high fever, HHE, or convulsions occurred after previous pertussis dose. Risk of hematoma in bleeding disorders.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
2 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| INFANRIX-IPV/HIB | 25 MCG / 0.5 ML | SUSPENSION | GLAXOSMITHKLINE INC | MARKETED | 02257122 |
| PENTACEL | 29 UNIT / 0.5 ML | SUSPENSION | SANOFI PASTEUR LIMITED | MARKETED | 02534797 |
| PENTACEL | 20 MCG / 0.5 ML | LIQUID ; POWDER FOR SOLUTION | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | 02231343 |
2 · Same class — other molecules in ATC J07CA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Diphtheria-Pertussis-Poliomyelitis-Tetanus | ADACEL-POLIO · BOOSTRIX-POLIO · DPT POLIO ADSORBED VACCINES · INFANRIX HEXA · +2 more | 7 | 4 | Yes |
| Dipht-Hemoph Influen B-Pertuss-Polio-Tetanus | INFANRIX-IPV/HIB · PEDIACEL · PENTACEL | 4 | 2 | Yes |
| Diphtheria-Poliomyelitis-Tetanus | DT POLIO ADSORBED - SUS IM · TD POLIO ADSORBED | 2 | 0 | Not in Canada |
| Bacterial And Viral Vaccines, Combined | T POLIO ADSORBED | 1 | 0 | Not in Canada |
| Typhoid-Hepatitis A | VIVAXIM | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
4 · Fixed-dose combinations with Canadian supply
| Product | Active ingredients | Holder | Status | DIN |
|---|---|---|---|---|
| ADACEL-POLIO | POLIOVIRUS TYPE 1 MAHONEY (INACTIVATED) : 29 UNIT / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 5 MCG / 0.5 ML DIPHTHERIA TOXOID : 2 LF / 0.5 ML PERTUSSIS TOXOID : 2.5 MCG / 0.5 ML TETANUS TOXOID : 5 LF / 0.5 ML POLIOVIRUS TYPE 2 MEF1 (INACTIVATED) : 7 UNIT / 0.5 ML POLIOVIRUS TYPE 3 SAUKETT (INACTIVATED) : 26 UNIT / 0.5 ML FIMBRIAE TYPES 2 AND 3 (FIM) : 5 MCG / 0.5 ML PERTACTIN : 3 MCG / 0.5 ML | SANOFI PASTEUR LIMITED | MARKETED | 02352044 |
| INFANRIX-IPV/HIB | FILAMENTOUS HAEMAGGLUTININ : 25 MCG / 0.5 ML HAEMOPHILUS INFLUENZAE TYPE B-PRP AND TETANUS TOXOID CONJUGATE (PRP-T) : 10 MCG / 0.5 ML INACTIVATED POLIOVIRUS TYPE II : 8 UNIT / 0.5 ML PERTUSSIS TOXOID : 25 MCG / 0.5 ML DIPHTHERIA TOXOID : 30 UNIT / 0.5 ML INACTIVATED POLIOVIRUS TYPE III : 32 UNIT / 0.5 ML TETANUS TOXOID : 40 UNIT / 0.5 ML PERTACTIN : 8 MCG / 0.5 ML INACTIVATED POLIOVIRUS TYPE I : 40 UNIT / 0.5 ML | GLAXOSMITHKLINE INC | MARKETED | 02257122 |
| QUADRACEL | TETANUS TOXOID : 5 LF / 0.5 ML FIMBRIAE TYPES 2 AND 3 (FIM) : 5 MCG / 0.5 ML POLIOVIRUS TYPE 1 MAHONEY (INACTIVATED) : 29 UNIT / 0.5 ML PERTACTIN : 3 MCG / 0.5 ML DIPHTHERIA TOXOID : 15 LF / 0.5 ML POLIOVIRUS TYPE 2 MEF1 (INACTIVATED) : 7 UNIT / 0.5 ML POLIOVIRUS TYPE 3 SAUKETT (INACTIVATED) : 26 UNIT / 0.5 ML PERTUSSIS TOXOID : 20 MCG / 0.5 ML FILAMENTOUS HAEMAGGLUTININ : 20 MCG / 0.5 ML | SANOFI PASTEUR LIMITED | MARKETED | 02534789 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.